Cervical Squamous Cell Carcinoma

◆

Subtypes

2

HPV-Associated Cervical Squamous Cell Carcinoma

The dominant subtype, accounting for the vast majority of cervical squamous cell carcinomas (~90-95%). Defined by persistent infection with high-risk HPV and identified pathologically by block-type p16 immunohistochemistry (a surrogate marker for high-risk HPV).

Show evidence (1 reference)

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"The 2020 WHO classification is focused on the distinction between HPV-associated and HPV-independent squamous cell carcinoma of the lower female genital organs."

The 2020 WHO classification codifies HPV-associated cervical SCC as a distinct etiologic subtype, with p16 IHC as the surrogate marker.

HPV-Independent Cervical Squamous Cell Carcinoma

A minority of cervical SCCs that are not driven by HPV. The 2020 WHO classification defines this subtype by absence of HPV association, with p16 immunohistochemistry used as the surrogate marker to assign cases to the HPV-associated versus HPV-independent categories. "Squamous cell carcinoma, NOS" is permitted when HPV status cannot be established.

Show evidence (1 reference)

DOI:10.1055/a-1545-4279 SUPPORT Human Clinical

"Immunohistochemical p16 expression is considered to be a surrogate marker for HPV association."

WHO 2020 establishes the HPV-associated vs HPV-independent dichotomy using p16 IHC, the basis for defining the HPV-independent subtype.

⚙

Pathophysiology

4

Persistent High-Risk HPV Infection

Persistent infection of the cervical squamous epithelium by high-risk HPV (most commonly HPV-16) is the main aetiological event in cervical squamous cell carcinoma. Persistent infection commits infected cells to a transforming viral cycle in which the E6 and E7 oncoproteins are continuously expressed.

Squamous epithelial cell link

Viral process link

Downstream

E6/E7 Inactivation of p53 and pRB

Show evidence (1 reference)

PMID:40216282 SUPPORT Human Clinical

"The main aetiological factor for developing cervical cancer is the persistent infection of Human papillomavirus (HPV)."

Ranasinghe & McMillan 2025 directly identify persistent high-risk HPV infection as the main aetiological event in cervical cancer, supporting this node as the initiating step of cervical squamous cell carcinoma pathophysiology.

E6/E7 Inactivation of p53 and pRB

HPV E6 causes degradation of p53, impairing the cellular stress response, while HPV E7 impairs the activity of the retinoblastoma protein (pRB), resulting in continuous cell cycle propagation. Combined loss of p53 and pRB function removes the principal checkpoints that normally restrain proliferation of damaged cells.

Squamous epithelial cell link

Negative regulation of p53 signaling link ↑ INCREASED

Downstream

Genomic Instability and CIN Progression

Show evidence (1 reference)

PMID:40216282 SUPPORT Human Clinical

"The E6 protein causes degradation of p53 leading to impaired cellular stress response. In contrast, the E7 protein impairs the activity of retinoblastoma protein (pRb) resulting in continuous cell cycle propagation."

Ranasinghe & McMillan 2025 directly state the E6/p53 degradation and E7/pRB inactivation mechanisms that define this node.

Genomic Instability and CIN Progression

Continuous cell-cycle propagation driven by HPV E6/E7 activity permits accumulation of DNA damage and progression of the affected squamous epithelium through cervical intraepithelial neoplasia (CIN1 -> CIN2 -> CIN3) before invasion.

Squamous epithelial cell link

Downstream

Stromal Invasion

Show evidence (1 reference)

PMID:40216282 SUPPORT Human Clinical

"The E7 protein impairs the activity of retinoblastoma protein (pRb) resulting in continuous cell cycle propagation."

Continuous cell-cycle propagation downstream of E7-mediated pRB inactivation is the proximate driver of accumulating DNA damage and stepwise CIN progression that defines this node.

Stromal Invasion

Invasive cervical squamous cell carcinoma is defined by breach of the basement membrane and invasion of the cervical stroma by malignant squamous cells, enabling lymphovascular spread and distant metastasis.

Squamous epithelial cell link

Show evidence (1 reference)

DOI:10.3390/jcm13154351 SUPPORT Human Clinical

"Stromal invasion and lymphovascular space involvement (LVSI) from pretreatment biopsy identify candidates for surgery, particularly for simple hysterectomy."

The Polish Society guidelines anchor stromal invasion (and lymphovascular space involvement) as the defining pathological feature distinguishing invasive cervical squamous cell carcinoma from precursor CIN lesions.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

5

Blood 1

Anemia Anemia (HP:0001903)

Constitutional 1

Pelvic Pain Pelvic pain (HP:0034267)

Other 3

Abnormal Vaginal Bleeding Abnormal vaginal bleeding (HP:0034263)

Postcoital Vaginal Bleeding Postcoital vaginal bleeding (HP:0034264)

Abnormal Vaginal Discharge Abnormal vaginal discharge (HP:0034269)

💊

Treatments

4

Radical Hysterectomy

Action: surgical procedure MAXO:0000004

Surgical management for early-stage disease.

Concurrent Chemoradiation

Action: radiation therapy MAXO:0000014

Concurrent platinum-based chemotherapy with radiotherapy followed by brachytherapy is the cornerstone of curative therapy for locally advanced cervical cancer. KEYNOTE-A18 now establishes pembrolizumab plus chemoradiation as a new standard for high-risk locally advanced disease.

Show evidence (2 references)

DOI:10.3390/jcm13154351 SUPPORT Human Clinical

"Locally Advanced Cancer: concurrent chemoradiation (CCRT) followed by brachytherapy (BRT) is the cornerstone treatment."

National guideline establishes CCRT + brachytherapy as cornerstone for locally advanced cervical cancer.

DOI:10.3390/curroncol33010048 SUPPORT Human Clinical

"For locally advanced disease, KEYNOTE-A18 establishes pembrolizumab plus chemoradiation as a new curative standard"

KEYNOTE-A18 has shifted standard-of-care for high-risk locally advanced cervical cancer to pembrolizumab + chemoradiation.

Pembrolizumab

Action: Pharmacotherapy NCIT:C15986

Agent: pembrolizumab ↗

Anti-PD-1 checkpoint inhibitor approved for metastatic and locally advanced cervical cancer. KEYNOTE-826 established benefit in metastatic PD-L1-positive disease and KEYNOTE-A18 in locally advanced disease.

HPV Vaccination

Action: vaccination MAXO:0001017

Prophylactic HPV vaccination is the primary preventive strategy. WHO elimination targets 90% of girls fully vaccinated by age 15.

🌍

Environmental Factors

2

Cigarette smoking

Cigarette smoking is an independent cervical-cancer risk factor whose effect does not require HPV co-infection to manifest, with a dose-response relationship and risk normalization roughly 15 years after smoking cessation. A 109-study meta-analysis found pooled RR 1.70 (95% CI 1.53-1.88) for invasive cervical cancer in current vs never smokers.

Show evidence (2 references)

DOI:10.1097/CEJ.0000000000000773 SUPPORT Human Clinical

"We included 109 studies providing a pooled RR of invasive CC and preinvasive lesions, respectively, of 1.70 [95% confidence interval (CI), 1.53–1.88] and 2.11 (95% CI, 1.85–2.39) for current versus never smokers"

Meta-analytic pooled RR establishing cigarette smoking as an independent risk factor for invasive cervical cancer.

DOI:10.1097/CEJ.0000000000000773 SUPPORT Human Clinical

"The risk of CC increased with pack-years and smoking duration and decreased linearly with time since quitting, reaching that of never smokers about 15 years after quitting."

Establishes dose-response and ~15-year cessation window for risk normalization.

High-Risk HPV Infection

Persistent infection with high-risk human papillomavirus (HPV) is the near-universal cause of cervical squamous cell carcinoma. HPV-16 and HPV-18 together account for approximately 70-71% of cases globally.

Show evidence (1 reference)

PMID:40216282 SUPPORT Human Clinical

"The main aetiological factor for developing cervical cancer is the persistent infection of Human papillomavirus (HPV)."

Ranasinghe & McMillan 2025 directly identify persistent HPV infection as the main aetiological factor for cervical cancer, supporting classification of high-risk HPV as the causal environmental driver.

{ }

Source YAML

click to show

name: Cervical Squamous Cell Carcinoma
creation_date: "2026-05-12T20:30:00Z"
updated_date: "2026-05-13T12:00:00Z"
category: Complex
disease_term:
  preferred_term: cervical squamous cell carcinoma
  term:
    id: MONDO:0006143
    label: cervical squamous cell carcinoma
parents:
- Cervical Cancer
description: >-
  Cervical squamous cell carcinoma (CSCC) is the most common histologic type
  of cervical cancer, accounting for approximately 70-80% of cases. It arises
  from the squamous epithelium of the ectocervix, predominantly at the
  squamocolumnar junction (the transformation zone). Nearly all cases are
  caused by persistent infection with high-risk human papillomavirus (HPV),
  most commonly HPV-16. The HPV oncoproteins E6 and E7 inactivate the tumor
  suppressors p53 and pRB, respectively, driving genomic instability and
  malignant transformation through a stepwise progression from cervical
  intraepithelial neoplasia (CIN1 -> CIN2 -> CIN3) to invasive carcinoma.
has_subtypes:
- name: HPV-Associated SCC
  display_name: HPV-Associated Cervical Squamous Cell Carcinoma
  description: >-
    The dominant subtype, accounting for the vast majority of cervical
    squamous cell carcinomas (~90-95%). Defined by persistent infection
    with high-risk HPV and identified pathologically by block-type p16
    immunohistochemistry (a surrogate marker for high-risk HPV).
  evidence:
  - reference: DOI:10.1055/a-1545-4279
    reference_title: "2020 WHO Classification of Female Genital Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The 2020 WHO classification is focused on the distinction between HPV-associated and HPV-independent squamous cell carcinoma of the lower female genital organs."
    explanation: The 2020 WHO classification codifies HPV-associated cervical SCC as a distinct etiologic subtype, with p16 IHC as the surrogate marker.
- name: HPV-Independent SCC
  display_name: HPV-Independent Cervical Squamous Cell Carcinoma
  description: >-
    A minority of cervical SCCs that are not driven by HPV. The 2020 WHO
    classification defines this subtype by absence of HPV association, with
    p16 immunohistochemistry used as the surrogate marker to assign cases
    to the HPV-associated versus HPV-independent categories. "Squamous cell
    carcinoma, NOS" is permitted when HPV status cannot be established.
  evidence:
  - reference: DOI:10.1055/a-1545-4279
    reference_title: "2020 WHO Classification of Female Genital Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Immunohistochemical p16 expression is considered to be a surrogate marker for HPV association."
    explanation: WHO 2020 establishes the HPV-associated vs HPV-independent dichotomy using p16 IHC, the basis for defining the HPV-independent subtype.
stages:
- name: CIN1
  description: >-
    Cervical intraepithelial neoplasia grade 1 (low-grade squamous
    intraepithelial lesion), typically reflecting productive high-risk HPV
    infection of the cervical squamous epithelium; most CIN1 lesions
    regress spontaneously.
- name: CIN2
  description: >-
    Cervical intraepithelial neoplasia grade 2, an intermediate-grade
    precancerous lesion with dysplastic changes extending into the middle
    third of the epithelium, considered part of the high-grade squamous
    intraepithelial lesion (HSIL) category in two-tier systems.
- name: CIN3
  description: >-
    Cervical intraepithelial neoplasia grade 3 (high-grade squamous
    intraepithelial lesion), with dysplastic cells occupying the full
    thickness of the squamous epithelium. CIN3 is the immediate precursor
    lesion to invasive cervical squamous cell carcinoma.
- name: Invasive Squamous Cell Carcinoma
  description: >-
    Invasive cervical squamous cell carcinoma, defined by breach of the
    basement membrane and stromal invasion by malignant squamous cells.
    Invasion permits lymphovascular spread and distant metastasis.
pathophysiology:
- name: Persistent High-Risk HPV Infection
  description: >-
    Persistent infection of the cervical squamous epithelium by high-risk
    HPV (most commonly HPV-16) is the main aetiological event in cervical
    squamous cell carcinoma. Persistent infection commits infected cells to
    a transforming viral cycle in which the E6 and E7 oncoproteins are
    continuously expressed.
  notes: >-
    Viral DNA integration into the host genome, with disruption of the E2
    repressor and consequent dysregulation of E6/E7, is a frequently
    observed molecular event in cervical squamous cell carcinoma but is
    not modeled here as a separate atomic node because it is not directly
    quoted from the cited mechanistic review.
  evidence:
  - reference: PMID:40216282
    reference_title: "Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main aetiological factor for developing cervical cancer is the persistent infection of Human papillomavirus (HPV)."
    explanation: >-
      Ranasinghe & McMillan 2025 directly identify persistent high-risk HPV
      infection as the main aetiological event in cervical cancer, supporting
      this node as the initiating step of cervical squamous cell carcinoma
      pathophysiology.
  cell_types:
  - preferred_term: Squamous epithelial cell
    term:
      id: CL:0000076
      label: squamous epithelial cell
  biological_processes:
  - preferred_term: Viral process
    term:
      id: GO:0016032
      label: viral process
  downstream:
  - target: E6/E7 Inactivation of p53 and pRB
    evidence:
    - reference: PMID:40216282
      reference_title: "Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The E6 and E7 oncoproteins produced by HPV mainly contribute to the carcinogenic process by inhibiting the function of tumour suppressor genes."
      explanation: >-
        Ranasinghe & McMillan 2025 directly connect persistent HPV infection
        to downstream tumor-suppressor inactivation by the E6 and E7
        oncoproteins, supporting this causal edge.
- name: E6/E7 Inactivation of p53 and pRB
  description: >-
    HPV E6 causes degradation of p53, impairing the cellular stress
    response, while HPV E7 impairs the activity of the retinoblastoma
    protein (pRB), resulting in continuous cell cycle propagation.
    Combined loss of p53 and pRB function removes the principal
    checkpoints that normally restrain proliferation of damaged cells.
  notes: >-
    Mechanistically, p53 degradation by E6 proceeds via the E6AP ubiquitin
    ligase and pRB inactivation by E7 releases E2F transcription factors
    driving S-phase entry; these molecular details are well established
    but are not directly stated in the abstract cited here.
  evidence:
  - reference: PMID:40216282
    reference_title: "Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The E6 protein causes degradation of p53 leading to impaired cellular stress response. In contrast, the E7 protein impairs the activity of retinoblastoma protein (pRb) resulting in continuous cell cycle propagation."
    explanation: >-
      Ranasinghe & McMillan 2025 directly state the E6/p53 degradation and
      E7/pRB inactivation mechanisms that define this node.
  cell_types:
  - preferred_term: Squamous epithelial cell
    term:
      id: CL:0000076
      label: squamous epithelial cell
  biological_processes:
  - preferred_term: Negative regulation of p53 signaling
    term:
      id: GO:1901797
      label: negative regulation of signal transduction by p53 class mediator
    modifier: INCREASED
  downstream:
  - target: Genomic Instability and CIN Progression
    evidence:
    - reference: PMID:40216282
      reference_title: "Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The E7 protein impairs the activity of retinoblastoma protein (pRb) resulting in continuous cell cycle propagation."
      explanation: >-
        Continuous cell-cycle propagation driven by E7-mediated pRB
        inactivation is the immediate upstream driver of accumulating DNA
        damage and stepwise CIN progression in HPV-driven cervical squamous
        epithelium.
- name: Genomic Instability and CIN Progression
  description: >-
    Continuous cell-cycle propagation driven by HPV E6/E7 activity permits
    accumulation of DNA damage and progression of the affected squamous
    epithelium through cervical intraepithelial neoplasia
    (CIN1 -> CIN2 -> CIN3) before invasion.
  notes: >-
    APOBEC-driven mutational signatures and copy-number changes are
    frequently described in cervical squamous cell carcinoma genomes, but
    are listed only as emerging biomarkers (not mechanistic claims) in the
    cited reviews and are therefore not asserted with primary evidence here.
  evidence:
  - reference: PMID:40216282
    reference_title: "Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The E7 protein impairs the activity of retinoblastoma protein (pRb) resulting in continuous cell cycle propagation."
    explanation: >-
      Continuous cell-cycle propagation downstream of E7-mediated pRB
      inactivation is the proximate driver of accumulating DNA damage and
      stepwise CIN progression that defines this node.
  cell_types:
  - preferred_term: Squamous epithelial cell
    term:
      id: CL:0000076
      label: squamous epithelial cell
  downstream:
  - target: Stromal Invasion
    evidence:
    - reference: DOI:10.3390/jcm13154351
      reference_title: "The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Stromal invasion and lymphovascular space involvement (LVSI) from pretreatment biopsy identify candidates for surgery, particularly for simple hysterectomy."
      explanation: >-
        The Polish Society guidelines identify stromal invasion as the defining
        pathological endpoint that distinguishes invasive cervical squamous cell
        carcinoma from precursor CIN lesions, establishing it as the clinical
        consequence of the CIN progression sequence.
- name: Stromal Invasion
  description: >-
    Invasive cervical squamous cell carcinoma is defined by breach of the
    basement membrane and invasion of the cervical stroma by malignant
    squamous cells, enabling lymphovascular spread and distant metastasis.
  evidence:
  - reference: DOI:10.3390/jcm13154351
    reference_title: "The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Stromal invasion and lymphovascular space involvement (LVSI) from pretreatment biopsy identify candidates for surgery, particularly for simple hysterectomy."
    explanation: >-
      The Polish Society guidelines anchor stromal invasion (and lymphovascular
      space involvement) as the defining pathological feature distinguishing
      invasive cervical squamous cell carcinoma from precursor CIN lesions.
  cell_types:
  - preferred_term: Squamous epithelial cell
    term:
      id: CL:0000076
      label: squamous epithelial cell
phenotypes:
- category: Reproductive
  name: Abnormal Vaginal Bleeding
  phenotype_term:
    preferred_term: Abnormal vaginal bleeding
    term:
      id: HP:0034263
      label: Abnormal vaginal bleeding
- category: Reproductive
  name: Postcoital Vaginal Bleeding
  phenotype_term:
    preferred_term: Postcoital vaginal bleeding
    term:
      id: HP:0034264
      label: Postcoital vaginal bleeding
- category: Reproductive
  name: Abnormal Vaginal Discharge
  phenotype_term:
    preferred_term: Abnormal vaginal discharge
    term:
      id: HP:0034269
      label: Abnormal vaginal discharge
- category: Pain
  name: Pelvic Pain
  phenotype_term:
    preferred_term: Pelvic pain
    term:
      id: HP:0034267
      label: Pelvic pain
- category: Hematologic
  name: Anemia
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
environmental:
- name: Cigarette smoking
  effect: HARMFUL
  description: >-
    Cigarette smoking is an independent cervical-cancer risk factor whose
    effect does not require HPV co-infection to manifest, with a dose-response
    relationship and risk normalization roughly 15 years after smoking
    cessation. A 109-study meta-analysis found pooled RR 1.70 (95% CI
    1.53-1.88) for invasive cervical cancer in current vs never smokers.
  evidence:
  - reference: DOI:10.1097/CEJ.0000000000000773
    reference_title: "Dose-risk relationships between cigarette smoking and cervical cancer: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We included 109 studies providing a pooled RR of invasive CC and preinvasive lesions, respectively, of 1.70 [95% confidence interval (CI), 1.53–1.88] and 2.11 (95% CI, 1.85–2.39) for current versus never smokers"
    explanation: Meta-analytic pooled RR establishing cigarette smoking as an independent risk factor for invasive cervical cancer.
  - reference: DOI:10.1097/CEJ.0000000000000773
    reference_title: "Dose-risk relationships between cigarette smoking and cervical cancer: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The risk of CC increased with pack-years and smoking duration and decreased linearly with time since quitting, reaching that of never smokers about 15 years after quitting."
    explanation: Establishes dose-response and ~15-year cessation window for risk normalization.
- name: High-Risk HPV Infection
  effect: CAUSAL
  description: >-
    Persistent infection with high-risk human papillomavirus (HPV) is the
    near-universal cause of cervical squamous cell carcinoma. HPV-16 and
    HPV-18 together account for approximately 70-71% of cases globally.
  evidence:
  - reference: PMID:40216282
    reference_title: "Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The main aetiological factor for developing cervical cancer is the persistent infection of Human papillomavirus (HPV)."
    explanation: >-
      Ranasinghe & McMillan 2025 directly identify persistent HPV infection
      as the main aetiological factor for cervical cancer, supporting
      classification of high-risk HPV as the causal environmental driver.
treatments:
- name: Radical Hysterectomy
  description: Surgical management for early-stage disease.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Concurrent Chemoradiation
  description: >-
    Concurrent platinum-based chemotherapy with radiotherapy followed by
    brachytherapy is the cornerstone of curative therapy for locally
    advanced cervical cancer. KEYNOTE-A18 now establishes pembrolizumab
    plus chemoradiation as a new standard for high-risk locally advanced
    disease.
  evidence:
  - reference: DOI:10.3390/jcm13154351
    reference_title: "The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Locally Advanced Cancer: concurrent chemoradiation (CCRT) followed by brachytherapy (BRT) is the cornerstone treatment."
    explanation: National guideline establishes CCRT + brachytherapy as cornerstone for locally advanced cervical cancer.
  - reference: DOI:10.3390/curroncol33010048
    reference_title: "Advances in Screening, Immunotherapy, Targeted Agents, and Precision Surgery in Cervical Cancer: A Comprehensive Clinical Review (2018–2025)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For locally advanced disease, KEYNOTE-A18 establishes pembrolizumab plus chemoradiation as a new curative standard"
    explanation: KEYNOTE-A18 has shifted standard-of-care for high-risk locally advanced cervical cancer to pembrolizumab + chemoradiation.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
- name: Pembrolizumab
  description: >-
    Anti-PD-1 checkpoint inhibitor approved for metastatic and locally
    advanced cervical cancer. KEYNOTE-826 established benefit in metastatic
    PD-L1-positive disease and KEYNOTE-A18 in locally advanced disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pembrolizumab
      term:
        id: NCIT:C106432
        label: Pembrolizumab
- name: HPV Vaccination
  description: >-
    Prophylactic HPV vaccination is the primary preventive strategy. WHO
    elimination targets 90% of girls fully vaccinated by age 15.
  treatment_term:
    preferred_term: vaccination
    term:
      id: MAXO:0001017
      label: vaccination
datasets:

📚

References & Deep Research

Deep Research

1

Falcon ▸

1. Disease Information

Edison Scientific Literature 38 citations 2026-05-12T17:59:03.232606

1. Disease Information

1.1 Definition and current understanding

Cervical squamous cell carcinoma (CSCC) is the most common histologic subtype of cervical cancer, arising from squamous epithelium of the cervix and strongly linked to persistent high‑risk human papillomavirus (hrHPV) infection. CSCC accounts for ~85% of cervical cancers in a recent clinical review spanning 2018–2025, consistent with long‑standing epidemiology. (nagdev2026advancesinscreening pages 1-2)

1.2 Key identifiers and classification

A structured summary of identifiers and nomenclature supported by retrieved sources is provided in the embedded artifact.

Identifier type	Code/ID	Preferred label	Synonyms/alternate names	Source/URL/date
OpenTargets / EFO proxy	EFO_1000172	cervical squamous cell carcinoma	CSCC; cervical SCC	OpenTargets disease-target association result for “cervical squamous cell carcinoma” (OpenTargets Search: cervical squamous cell carcinoma)
MONDO	not found in retrieved sources	Cervical squamous cell carcinoma	CSCC	No MONDO identifier explicitly reported in retrieved evidence; OpenTargets EFO proxy available instead (OpenTargets Search: cervical squamous cell carcinoma)
MeSH	not found in retrieved sources	not found in retrieved sources	“Uterine Cervical Neoplasms” mentioned as MeSH search terminology in cervical cancer literature, but no explicit MeSH ID for CSCC in retrieved evidence	Bobdey et al., Burden of cervical cancer and role of screening in India; https://doi.org/10.4103/0971-5851.195751; 2016 (snippet notes use of MeSH terms) (OpenTargets Search: cervical squamous cell carcinoma)
ICD-10	C53	cervical cancer / cervix uteri cancer	invasive cervical cancer	Noguchi et al., Recent Increasing Incidence of Early-Stage Cervical Cancers of the Squamous Cell Carcinoma Subtype among Young Women; https://doi.org/10.3390/ijerph17207401; 2020 (“invasive cancer (C53 in ICD-10)”) (OpenTargets Search: cervical squamous cell carcinoma)
WHO 2020 classification concept	not an external code in retrieved sources	HPV-associated squamous cell carcinoma of the cervix	HPV-associated cervical SCC	Höhn et al., 2020 WHO Classification of Female Genital Tumors; https://doi.org/10.1055/a-1545-4279; 2021 (WHO distinguishes HPV-associated vs HPV-independent SCC) (hohn20212020whoclassification pages 1-2, hohn20212020whoclassification pages 2-4)
WHO 2020 classification concept	not an external code in retrieved sources	HPV-independent squamous cell carcinoma of the cervix	HPV-independent cervical SCC; squamous cell carcinoma, NOS acceptable if classification unavailable	Höhn et al., 2020 WHO Classification of Female Genital Tumors; https://doi.org/10.1055/a-1545-4279; 2021; and Polish Society guidelines summarizing WHO-style classification; https://doi.org/10.3390/jcm13154351; 2024 (hohn20212020whoclassification pages 1-2, sznurkowski2024thepolishsociety pages 3-4, hohn20212020whoclassification pages 2-4)
Pathology surrogate marker	p16 (block-type expression)	surrogate marker for HPV association in cervical SCC	p16 IHC; strong diffuse “block” staining	Höhn et al., 2020 WHO Classification of Female Genital Tumors; https://doi.org/10.1055/a-1545-4279; 2021 (p16 is a reliable, though imperfect, surrogate for HPV association) (hohn20212020whoclassification pages 1-2, hohn20212020whoclassification pages 2-4)
Histopathologic reporting term	NOS	squamous cell carcinoma, NOS	SCC, NOS	WHO 2020 summary indicates SCC, NOS is acceptable when HPV-association cannot be established by p16 and/or HPV testing (hohn20212020whoclassification pages 4-6, hohn20212020whoclassification pages 2-4)
Histologic subtype / nomenclature	not a code	non-keratinizing squamous cell carcinoma	non-keratinizing SCC	Mehla, Study of Cervical Carcinomas Diagnosed in 2015-2022...; 2025 (summarizes WHO-recognized morphologic subtypes including keratinizing, non-keratinizing, papillary) (mehla2025studyofcervical pages 10-12)
Histologic subtype / nomenclature	not a code	keratinizing squamous cell carcinoma	keratinizing SCC	Mehla, Study of Cervical Carcinomas Diagnosed in 2015-2022...; 2025; Polish Society guideline notes HPV-independent tumors are often keratinizing (sznurkowski2024thepolishsociety pages 2-3, mehla2025studyofcervical pages 10-12)

Table: This table summarizes the key identifiers, classification concepts, and nomenclature for cervical squamous cell carcinoma supported by the retrieved evidence. It highlights where formal identifiers were not explicitly found and preserves WHO 2020 terminology relevant for pathology reporting.

Key classification concept: The WHO 2020 classification emphasizes reporting cervical squamous carcinomas as HPV‑associated versus HPV‑independent, using p16 immunohistochemistry (IHC) block‑type positivity as a surrogate marker for HPV association; when classification cannot be established, “squamous cell carcinoma, NOS” is acceptable. (hohn20212020whoclassification pages 2-4, hohn20212020whoclassification pages 1-2)

1.3 Synonyms/alternative names

Common terms in the retrieved literature include “cervical SCC” and “cervical squamous cell carcinoma (CSCC).” (nagdev2026advancesinscreening pages 1-2)

1.4 Evidence provenance (aggregated vs patient-level)

Most disease-level facts in this report derive from aggregated resources (GBD analyses, guideline consortia, and narrative/systematic reviews). (ma2025globalregionaland pages 2-3, fischerova2024theroleof pages 1-2, zhou2025globalcervicalcancer pages 1-2)

2. Etiology

2.1 Primary causal factors

Persistent infection with hrHPV is the dominant etiologic driver of cervical cancer: one 2024 screening-focused review states “over 95% of cervical cancers are attributable to HPV.” (goldstein2024thefutureof pages 1-2)

HPV16 and HPV18 contribute the majority of cases globally: estimates in retrieved sources include ~70% (review) and ~71% (global screening review). (nagdev2026advancesinscreening pages 1-2, goldstein2024thefutureof pages 1-2)

2.2 Risk factors (human epidemiology)

A concise, quantitative risk-factor table (restricted to effects explicitly present in retrieved evidence) is embedded below.

Factor (etiologic/risk/protective)	Evidence type	Quantitative effect (RR/HR/% attributable) if available	Key notes (HPV types, cofactors)	Best supporting citation info
Persistent high-risk HPV infection	Review / epidemiology	">95%" of cervical cancers attributable to HPV	Persistent hrHPV infection is the necessary/near-universal cause; CSCC is the dominant histology	Goldstein et al., 2024, DOI: 10.2147/IJWH.S474571 (goldstein2024thefutureof pages 1-2)
HPV16/18 attribution	Review / epidemiology	"~70%" of cases; alternatively "~71%" globally	HPV16 and HPV18 account for the majority of cervical cancers worldwide	Nagdev & Chittilla, 2026, DOI: 10.3390/curroncol33010048; Goldstein et al., 2024, DOI: 10.2147/IJWH.S474571 (nagdev2026advancesinscreening pages 1-2, goldstein2024thefutureof pages 1-2)
Smoking (current vs never)	Human epi / meta-analysis	Invasive cervical cancer RR 1.70 (95% CI 1.53–1.88)	Association persists independently of HPV infection; stronger for preinvasive disease	Malevolti et al., 2023, DOI: 10.1097/CEJ.0000000000000773 (malevolti2023doseriskrelationshipsbetween pages 5-6, malevolti2023doseriskrelationshipsbetween pages 1-2)
Smoking (former vs never)	Human epi / meta-analysis	Invasive cervical cancer RR 1.13 (95% CI 1.02–1.24)	Risk remains elevated after cessation but lower than for current smokers	Malevolti et al., 2023, DOI: 10.1097/CEJ.0000000000000773 (malevolti2023doseriskrelationshipsbetween pages 5-6, malevolti2023doseriskrelationshipsbetween pages 1-2)
Smoking intensity	Human epi / meta-analysis	10 cigarettes/day: RR 1.72 (95% CI 1.34–2.20); 20/day: RR 1.91 (1.46–2.49)	Dose-response relationship for invasive cervical cancer	Malevolti et al., 2023, DOI: 10.1097/CEJ.0000000000000773 (malevolti2023doseriskrelationshipsbetween pages 5-6)
Smoking cessation	Human epi / meta-analysis	Former vs current RR 0.72 at 10 years quit; 0.53 at 20 years quit; risk approaches never-smokers after ~15–16.5 years	Supports smoking cessation as a protective/risk-reducing intervention	Malevolti et al., 2023, DOI: 10.1097/CEJ.0000000000000773 (malevolti2023doseriskrelationshipsbetween pages 5-6, malevolti2023doseriskrelationshipsbetween pages 1-2, malevolti2023doseriskrelationshipsbetween pages 6-7)
HIV infection	Review / epidemiology	Quantitative estimate not given in retrieved context; described as "several-fold increases in incidence among HIV-positive women"	Major cofactor promoting HPV persistence/progression; also highlighted in recent reviews/guidelines	Jouya et al., 2026, DOI: 10.3390/jcm15031079; Nagdev & Chittilla, 2026, DOI: 10.3390/curroncol33010048 (jouya2026cervicalcancerepidemiology pages 12-13, nagdev2026advancesinscreening pages 1-2)
High parity	Review / epidemiology	Quantitative estimate not given in retrieved context	Reproductive cofactor associated with higher risk; often grouped with early sexual debut/multiple partners	Jouya et al., 2026, DOI: 10.3390/jcm15031079 (jouya2026cervicalcancerepidemiology pages 12-13)
Unsafe sex / sexual exposure	Population burden analysis	Identified as a principal attributable risk factor for DALYs; no numeric fraction in retrieved excerpt	Captures HPV acquisition risk and broader sexual-behavior contribution	Shao et al., 2026, DOI: 10.3389/fpubh.2026.1702186 (shao2026globaltrendsand pages 1-2)
HPV vaccination	Guideline / prevention review	WHO target: 90% of girls vaccinated by age 15	Primary prevention; recent guidance also notes single-dose strategies under evaluation/implementation	Zhou et al., 2025, DOI: 10.1186/s12916-025-03897-3; Jouya et al., 2026, DOI: 10.3390/jcm15031079 (zhou2025globalcervicalcancer pages 1-2, jouya2026cervicalcancerepidemiology pages 12-13)
Organized cervical screening	Guideline / prevention review	WHO target: 70% screened with high-performance tests by ages 35 and 45	Secondary prevention; primary HPV testing, self-sampling, methylation triage and AI-assisted tools are emerging	Zhou et al., 2025, DOI: 10.1186/s12916-025-03897-3; Goldstein et al., 2024, DOI: 10.2147/IJWH.S474571 (zhou2025globalcervicalcancer pages 1-2, goldstein2024thefutureof pages 1-2)
Treatment of screen-detected disease	Guideline / prevention	WHO target: 90% of women with cervical disease receiving appropriate treatment	Tertiary/secondary prevention bridge in WHO elimination framework	Zhou et al., 2025, DOI: 10.1186/s12916-025-03897-3 (zhou2025globalcervicalcancer pages 1-2)
Elimination threshold	Guideline / global strategy	Incidence target: <4 new cases per 100,000 women per year	Defines cervical cancer elimination as a public health problem	Zhou et al., 2025, DOI: 10.1186/s12916-025-03897-3; Shao et al., 2026, DOI: 10.3389/fpubh.2026.1702186 (zhou2025globalcervicalcancer pages 1-2, shao2026globaltrendsand pages 1-2)

Table: This table summarizes the main etiologic drivers, established risk cofactors, and protective/preventive measures for cervical squamous cell carcinoma using only quantitative findings explicitly available in the retrieved evidence. It is useful for quickly separating causal HPV biology from modifiable cofactors and current WHO-aligned prevention strategies.

Smoking: A 2023 systematic review/meta‑analysis (109 studies) reported pooled RR 1.70 (95% CI 1.53–1.88) for invasive cervical cancer in current vs never smokers, and RR 1.13 (95% CI 1.02–1.24) for former vs never smokers, with dose–response and risk reduction after cessation (risk approaching never smokers after ~15–16.5 years). (malevolti2023doseriskrelationshipsbetween pages 1-2, malevolti2023doseriskrelationshipsbetween pages 5-6)

HIV/immunosuppression: A 2026 epidemiology review reports “several‑fold increases in incidence among HIV‑positive women,” supporting HIV as a major cofactor that accelerates HPV persistence/progression. (jouya2026cervicalcancerepidemiology pages 12-13)

Reproductive/sexual cofactors: Early sexual debut, multiple partners, and high parity are cited as important cofactors in a 2026 epidemiology review. (jouya2026cervicalcancerepidemiology pages 12-13)

2.3 Protective factors

HPV vaccination is the major primary preventive factor within the WHO elimination framework (targets described below). (zhou2025globalcervicalcancer pages 1-2)

Smoking cessation is protective: dose–response meta-analysis indicates risk declines with time since quitting and approximates never-smoker risk after ~15–16.5 years. (malevolti2023doseriskrelationshipsbetween pages 5-6, malevolti2023doseriskrelationshipsbetween pages 6-7)

2.4 Gene–environment interactions

Direct quantitative gene–environment interaction estimates were not identified in the retrieved sources during this tool session. Mechanistically, HPV-driven oncogenesis interacts with host immune status (e.g., HIV) and tobacco exposure, consistent with multi-factorial progression models discussed in reviews. (jouya2026cervicalcancerepidemiology pages 12-13, malevolti2023doseriskrelationshipsbetween pages 1-2)

3. Phenotypes (clinical presentation)

3.1 Common phenotypes (signs/symptoms)

Recent guideline and clinical review materials in the retrieved set describe typical presenting features including abnormal vaginal bleeding/discharge and pelvic pain (not always CSCC‑specific but common across cervical cancer). (nagdev2026advancesinscreening pages 1-2)

3.2 Suggested HPO terms (not exhaustive)

Because structured phenotype-frequency estimates were not retrieved in this session, the following HPO terms are suggested as standard mappings (frequency requires additional sourcing): - Abnormal uterine bleeding / postcoital bleeding: HP:0000132 (Abnormality of menstruation) or HP:0000858 (Menorrhagia) depending on context. - Vaginal discharge: HP:0000146 (Vaginal discharge). - Pelvic pain: HP:0002027 (Abdominal pain) / pelvic pain term where available in HPO. - Anemia (from bleeding): HP:0001903 (Anemia).

3.3 Quality-of-life impact

Direct QoL instrument values specific to CSCC were not extracted from the retrieved evidence in this session; however, guideline and review sources emphasize substantial morbidity in advanced disease and the importance of palliative care access. (zhou2025globalcervicalcancer pages 1-2)

4. Genetic / Molecular Information

4.1 Somatic driver landscape (high-level)

OpenTargets disease–target associations for “cervical squamous cell carcinoma” highlight recurrently implicated cancer genes including PIK3CA, FBXW7, KMT2C, EP300, KMT2D, MAPK1, TP53, PTEN, STK11, NOTCH1, ERBB2, among others. This provides a curated pointer to commonly altered pathways in CSCC but is not itself a sequencing cohort analysis. (OpenTargets Search: cervical squamous cell carcinoma)

4.2 HPV-associated vs HPV-independent molecular patterns

A 2024 national guideline summary reports that HPV-associated cervical SCC is the dominant category (~90–95%), while HPV-independent SCC constitutes a minority (~5–7%) and is often associated with abnormal p53 staining and distinct molecular associations (e.g., KRAS, ARID1A, PTEN). (sznurkowski2024thepolishsociety pages 2-3)

4.3 Epigenetics

WHO 2020 discussions note p16 as a surrogate and acknowledge false negatives (e.g., p16 hypermethylation in a small fraction of CIN3), but systematic CSCC epigenomic signatures were not comprehensively extracted in this session. (hohn20212020whoclassification pages 6-8)

4.4 Pathogenic variants (germline)

No germline causal variant set (ClinVar/ClinGen-style) was retrieved for CSCC in this session; CSCC is typically infection-driven with predominantly somatic alterations. (goldstein2024thefutureof pages 1-2)

5. Environmental Information

5.1 Lifestyle/environmental contributors

Smoking is a robust, quantitatively supported risk factor with dose–response effects (RRs above). (malevolti2023doseriskrelationshipsbetween pages 5-6, malevolti2023doseriskrelationshipsbetween pages 1-2)

5.2 Infectious agents

High-risk HPV is the central infectious cause; HPV16/18 dominate global attribution fractions. (goldstein2024thefutureof pages 1-2, nagdev2026advancesinscreening pages 1-2)

6. Mechanism / Pathophysiology

6.1 Causal chain (HPV to CSCC)

A mechanistic review of HPV-associated lower genital tract cancers describes HPV oncoprotein-driven immune evasion, including upregulation of PD‑1/PD‑L1 axis and other checkpoint pathways (IDO1, LAG3, TIM3/Galectin‑9, TIGIT), providing a link from viral oncogenesis to an immunosuppressive tumor microenvironment and therapeutic vulnerability to checkpoint blockade. (zafar2025advancesandchallenges pages 7-8, zafar2025advancesandchallenges pages 20-21)

6.2 Immune microenvironment and checkpoint biology

HPV16 E6 has been described as promoting PD‑L1 expression via a miR‑143/HIF‑1α pathway; HPV-positive cervical cancer cells can also influence exosomal PD‑L1 expression by fibroblasts via CXCL10/CXCR3 and JAK‑STAT signaling, supporting multi-cell mechanisms for immune escape. (zafar2025advancesandchallenges pages 20-21)

6.3 Spatial transcriptomics: metabolic states and oncogenic regulators (2024 primary study)

A 2024 Journal of Translational Medicine study used spatial transcriptomics integrated with scRNA‑seq and TCGA analyses to map hypermetabolic versus hypometabolic regions in CSCC and identify regulatory factors. (zhou2024spatialtranscriptomicsreveals pages 1-2, zhou2024spatialtranscriptomicsreveals pages 9-12)

Key reported findings include: - Leading edge regions were characterized as uniformly hypermetabolic, whereas tumor core contained mixed hyper‑ and hypometabolic spots. (zhou2024spatialtranscriptomicsreveals pages 9-12) - APP was identified as a signaling molecule released by cancer cells with higher expression in hypermetabolic regions, and APP expression correlated with transcription factor TRPS1; functional knockdowns reduced proliferation/migration/invasion in vitro. (zhou2024spatialtranscriptomicsreveals pages 1-2, zhou2024spatialtranscriptomicsreveals pages 14-17) - Immune context differed by region, with PD‑L1 and IDO1 elevated in tumor center in one excerpted analysis, consistent with immune suppression. (zhou2024spatialtranscriptomicsreveals pages 14-17, zhou2024spatialtranscriptomicsreveals pages 6-9)

Visual evidence from the same study illustrating spatial hyper/hypometabolic regions and TRPS1/APP expression patterns is available in retrieved figure crops. (zhou2024spatialtranscriptomicsreveals media 5eccae45, zhou2024spatialtranscriptomicsreveals media 8e0f5cba, zhou2024spatialtranscriptomicsreveals media c108e719, zhou2024spatialtranscriptomicsreveals media f3ff4cda)

6.4 Suggested ontology mappings

GO biological processes (examples): - GO:0006915 (apoptotic process) - GO:0007049 (cell cycle) - GO:0006955 (immune response) - GO:0006096 (glycolytic process) / GO:0006119 (oxidative phosphorylation)

Cell Ontology (CL) cell types (examples): - CL:0000066 (epithelial cell) - CL:0000236 (B cell) - CL:0000623 (natural killer cell) - CL:0000904 (macrophage) - CL:0000451 (dendritic cell)

These ontology suggestions reflect mechanisms described in immune/multi‑omics sources, though specific term-to-claim mappings require additional structured curation beyond retrieved text. (zafar2025advancesandchallenges pages 20-21, zhou2024spatialtranscriptomicsreveals pages 14-17)

7. Anatomical Structures Affected

7.1 Organ and tissue level

Primary site is the cervix uteri, involving squamous epithelium (outer surface). (nagdev2026advancesinscreening pages 1-2)

Suggested UBERON terms (examples): - UBERON:0000002 (uterine cervix) - UBERON:0000458 (epithelium)

7.2 Subcellular/localization (GO-CC suggestions)

GO:0005634 (nucleus) for transcriptional regulators (e.g., TRPS1)
GO:0005886 (plasma membrane) for receptor/ligand interactions

8. Temporal Development (natural history)

The natural history from HPV infection through precancer to invasive carcinoma is described as well characterized in recent reviews, supporting screening and prevention paradigms. (nagdev2026advancesinscreening pages 1-2)

(Explicit quantitative transition probabilities and CIN stage durations were not extracted in the retrieved evidence during this session.)

9. Inheritance and Population

9.1 Epidemiology (recent global statistics)

Global incidence and mortality estimates reported in the retrieved sources include: - 2022: 661,021 new cases and 348,189 deaths (global elimination progress analysis). (zhou2025globalcervicalcancer pages 1-2) - GLOBOCAN 2022 (as cited in a 2026 clinical review): 662,000 new cases and 349,000 deaths, with mortality rate 7.1 per 100,000. (nagdev2026advancesinscreening pages 1-2) - 2021 (GBD-based estimates): 667,000 incident cases and 297,000 deaths; ~7.44 million DALYs attributed to cervical cancer. (ma2025globalregionaland pages 2-3)

Health inequities are substantial: one 2026 review states that over 80% of cervical cancer deaths occur in low-HDI settings. (jouya2026cervicalcancerepidemiology pages 12-13)

9.2 Inheritance pattern

CSCC is predominantly infection-associated and not typically inherited as a Mendelian disorder in the retrieved sources. (goldstein2024thefutureof pages 1-2)

10. Diagnostics

10.1 Screening and diagnostic pathway (current practice and developments)

Recent screening developments include primary HPV testing, HPV self‑sampling, and molecular triage strategies (DNA methylation assays, dual-stain cytology), as summarized in a 2024 review on the future of cervical screening. (goldstein2024thefutureof pages 1-2)

10.2 Pathology / biomarkers

WHO 2020 recommends distinguishing HPV-associated from HPV-independent squamous carcinomas and identifies p16 block staining as a reliable (imperfect) surrogate for HPV association; when uncertain, SCC NOS is acceptable. (hohn20212020whoclassification pages 2-4)

10.3 Imaging/staging (2023 guideline update summarized in 2024)

The ESGO/ESTRO/ESP imaging update (2023) recommends: - Pelvic MRI or expert transvaginal/transrectal ultrasound for local tumor delineation and assessing invasion. (fischerova2024theroleof pages 1-2) - Contrast-enhanced CT or 18F‑FDG PET/CT for extrapelvic spread in locally advanced disease or when suspicious nodes are present. (fischerova2024theroleof pages 1-2)

MRI is emphasized as modality of choice for local staging; PET/CT is valuable for nodal/distant disease detection but less optimal for local staging due to soft tissue limitations. (fischerova2024theroleof pages 7-8)

11. Outcome / Prognosis

11.1 Prognostic biomarkers and microenvironment

Spatial transcriptomics evidence suggests that elevated APP and TRPS1 correlate with poorer survival in TCGA CSCC cohort (p-values reported) and promote aggressive phenotypes in vitro, supporting their candidacy as prognostic/biological markers. (zhou2024spatialtranscriptomicsreveals pages 14-17)

11.2 Advanced disease outcomes and unmet need

A 2024 review on advanced/recurrent cervical cancer notes poor prognosis historically and summarizes improved outcomes with immunotherapy-based regimens. (zafar2025advancesandchallenges pages 7-8)

(Registry-derived 5‑year survival stratified by stage/histology was not retrieved in this session.)

12. Treatment

12.1 Standard local therapy (curative intent)

A mechanistic/clinical review notes standard local therapy for cervical cancer includes pelvic external beam radiotherapy (EBRT) with concurrent platinum-based chemotherapy and brachytherapy. (zafar2025advancesandchallenges pages 7-8)

12.2 Systemic therapy—immune checkpoint inhibitors (advanced/recurrent/metastatic)

Evidence extracted from an immunotherapy review includes: - KEYNOTE‑826 (pembrolizumab + chemotherapy ± bevacizumab): reported hazard ratio for death ~0.64 (36% reduction in risk of death) and survival prolongation by 12.1 months in the cited review excerpt. (dey2025immunotherapyincervical pages 7-8) - EMPOWER‑Cervical 1 (cemiplimab vs chemotherapy after platinum): median OS 12 vs 8.5 months; ORR 16.4% vs 6.3% in the cited review excerpt. (dey2025immunotherapyincervical pages 7-8)

A separate checkpoint-focused review reports pembrolizumab median OS 28.6 vs 16.5 months (trial context described) and reiterates cemiplimab OS 12 vs 8.5 months. (zafar2025advancesandchallenges pages 7-8)

12.3 Treatment-related toxicity (high level)

The immunotherapy review notes increased toxicities with combination regimens (e.g., anemia, neuropathy) and highlights immune-related adverse events as clinically relevant. (dey2025immunotherapyincervical pages 7-8)

12.4 Suggested MAXO mappings (examples)

MAXO:0000058 (radiotherapy)
MAXO:0000010 (chemotherapy)
MAXO term for immune checkpoint inhibitor therapy (e.g., “immune checkpoint inhibitor therapy”)—exact MAXO ID not retrieved in this session.

13. Prevention

13.1 WHO elimination strategy and targets

A 2025 global elimination analysis summarizes WHO’s 90–70–90 strategy by 2030: - 90% of girls vaccinated by age 15, - 70% of women screened with high-performance tests by ages 35 and 45, - 90% of women with cervical disease treated. (zhou2025globalcervicalcancer pages 1-2)

The elimination threshold is defined as <4 new cases per 100,000 women per year. (zhou2025globalcervicalcancer pages 1-2)

13.2 Screening technology modernization (2024)

Emerging modalities include rapid low-cost HPV testing, self-sampling, DNA methylation assays, and AI-assisted digital colposcopy interpretation, as summarized in a 2024 screening review. (goldstein2024thefutureof pages 1-2)

14. Other Species / Natural Disease

No cross-species naturally occurring CSCC analog with comparable HPV-driven etiology was retrieved in this session. Comparative HPV-associated squamous carcinomas across lower genital tract sites are discussed broadly in HPV-related reviews, but not as a dedicated veterinary natural disease section. (zafar2025advancesandchallenges pages 7-8)

15. Model Organisms

Specific in vivo model organism systems (e.g., HPV transgenic mouse models), organoids, or PDX resources were not retrieved in this session. The spatial transcriptomics CSCC work used human FFPE tumors integrated with scRNA-seq and in vitro functional assays (HeLa knockdowns), which constitutes a human tissue + cell line translational model rather than an animal model. (zhou2024spatialtranscriptomicsreveals pages 14-17, zhou2024spatialtranscriptomicsreveals pages 1-2)

Recent developments (2023–2024 highlights)

Spatial transcriptomics in CSCC (2024): identification of spatially resolved metabolic states and regulators (APP/TRPS1), with supporting figure evidence for regional metabolic patterns and gene expression. (zhou2024spatialtranscriptomicsreveals pages 1-2, zhou2024spatialtranscriptomicsreveals pages 14-17, zhou2024spatialtranscriptomicsreveals media 5eccae45, zhou2024spatialtranscriptomicsreveals media f3ff4cda)
Updated European imaging recommendations (2023 update, published 2024): stronger operational role for expert ultrasound and MRI in local staging and PET/CT or CECT for extrapelvic evaluation in higher-risk scenarios. (fischerova2024theroleof pages 1-2, fischerova2024theroleof pages 7-8)
Smoking risk quantification updated meta-analysis (2023): robust pooled RRs and cessation timelines relevant to prevention counseling. (malevolti2023doseriskrelationshipsbetween pages 1-2, malevolti2023doseriskrelationshipsbetween pages 5-6)
Screening innovation synthesis (2024): primary HPV testing, self-sampling, methylation triage, dual stain cytology, and AI-enabled tools highlighted as near-term implementation candidates. (goldstein2024thefutureof pages 1-2)

Embedded figure evidence (spatial transcriptomics)

The following retrieved figure crops from the 2024 CSCC spatial transcriptomics study support claims about metabolic regions and APP/TRPS1 spatial patterns: hyper/hypometabolic region maps and TRPS1/APP spatial expression panels. (zhou2024spatialtranscriptomicsreveals media 5eccae45, zhou2024spatialtranscriptomicsreveals media 8e0f5cba, zhou2024spatialtranscriptomicsreveals media c108e719, zhou2024spatialtranscriptomicsreveals media f3ff4cda)

Key gaps (not found in retrieved sources in this session)

MONDO and MeSH unique identifiers for CSCC (codes not explicitly captured in retrieved texts). (OpenTargets Search: cervical squamous cell carcinoma)
Detailed phenotype frequencies mapped to HPO and validated QoL instrument statistics specific to CSCC.
Comprehensive germline variant catalog and population allele frequencies.
Dedicated model organism summaries (HPV transgenic mice, organoids, PDX) with citations.

These gaps reflect limitations of the retrieved document set rather than absence of knowledge in the broader literature.

References

(nagdev2026advancesinscreening pages 1-2): Priyanka Nagdev and Mythri Chittilla. Advances in screening, immunotherapy, targeted agents, and precision surgery in cervical cancer: a comprehensive clinical review (2018–2025). Current Oncology, Jan 2026. URL: https://doi.org/10.3390/curroncol33010048, doi:10.3390/curroncol33010048. This article has 1 citations.
(OpenTargets Search: cervical squamous cell carcinoma): Open Targets Query (cervical squamous cell carcinoma, 39 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(hohn20212020whoclassification pages 1-2): Anne Kathrin Höhn, Christine E. Brambs, Grit Gesine Ruth Hiller, Doris May, Elisa Schmoeckel, and Lars-Christian Horn. 2020 who classification of female genital tumors. Geburtshilfe und Frauenheilkunde, 81:1145-1153, Oct 2021. URL: https://doi.org/10.1055/a-1545-4279, doi:10.1055/a-1545-4279. This article has 495 citations and is from a peer-reviewed journal.
(hohn20212020whoclassification pages 2-4): Anne Kathrin Höhn, Christine E. Brambs, Grit Gesine Ruth Hiller, Doris May, Elisa Schmoeckel, and Lars-Christian Horn. 2020 who classification of female genital tumors. Geburtshilfe und Frauenheilkunde, 81:1145-1153, Oct 2021. URL: https://doi.org/10.1055/a-1545-4279, doi:10.1055/a-1545-4279. This article has 495 citations and is from a peer-reviewed journal.
(sznurkowski2024thepolishsociety pages 3-4): Jacek J. Sznurkowski, Lubomir Bodnar, Łukasz Szylberg, Agnieszka Zołciak-Siwinska, Anna Dańska-Bidzińska, Dagmara Klasa-Mazurkiewicz, Agnieszka Rychlik, Artur Kowalik, Joanna Streb, Mariusz Bidziński, and Włodzimierz Sawicki. The polish society of gynecological oncology guidelines for the diagnosis and treatment of cervical cancer (v2024.0). Journal of Clinical Medicine, 13:4351, Jul 2024. URL: https://doi.org/10.3390/jcm13154351, doi:10.3390/jcm13154351. This article has 10 citations.
(hohn20212020whoclassification pages 4-6): Anne Kathrin Höhn, Christine E. Brambs, Grit Gesine Ruth Hiller, Doris May, Elisa Schmoeckel, and Lars-Christian Horn. 2020 who classification of female genital tumors. Geburtshilfe und Frauenheilkunde, 81:1145-1153, Oct 2021. URL: https://doi.org/10.1055/a-1545-4279, doi:10.1055/a-1545-4279. This article has 495 citations and is from a peer-reviewed journal.
(mehla2025studyofcervical pages 10-12): S Mehla. Study of cervical carcinomas diagnosed in 2015-2022 at the pathological anatomy clinic of hospital of luhs kauno clinics. Unknown journal, 2025.
(sznurkowski2024thepolishsociety pages 2-3): Jacek J. Sznurkowski, Lubomir Bodnar, Łukasz Szylberg, Agnieszka Zołciak-Siwinska, Anna Dańska-Bidzińska, Dagmara Klasa-Mazurkiewicz, Agnieszka Rychlik, Artur Kowalik, Joanna Streb, Mariusz Bidziński, and Włodzimierz Sawicki. The polish society of gynecological oncology guidelines for the diagnosis and treatment of cervical cancer (v2024.0). Journal of Clinical Medicine, 13:4351, Jul 2024. URL: https://doi.org/10.3390/jcm13154351, doi:10.3390/jcm13154351. This article has 10 citations.
(ma2025globalregionaland pages 2-3): Yidi Ma, Xiaozhen Lai, and Hai Fang. Global, regional, and national disease burden and economic costs of cervical cancer (1991–2021): a multidimensional data synthesis analysis. Frontiers in Public Health, Sep 2025. URL: https://doi.org/10.3389/fpubh.2025.1633975, doi:10.3389/fpubh.2025.1633975. This article has 3 citations.
(fischerova2024theroleof pages 1-2): Daniela Fischerova, Filip Frühauf, Andrea Burgetova, Ingfrid S. Haldorsen, Elena Gatti, and David Cibula. The role of imaging in cervical cancer staging: esgo/estro/esp guidelines (update 2023). Cancers, 16:775, Feb 2024. URL: https://doi.org/10.3390/cancers16040775, doi:10.3390/cancers16040775. This article has 50 citations.
(zhou2025globalcervicalcancer pages 1-2): Liangru Zhou, Yi Li, Hongyun Wang, Ruixi Qin, Zhen Han, and Ruifeng Li. Global cervical cancer elimination: quantifying the status, progress, and gaps. BMC Medicine, Feb 2025. URL: https://doi.org/10.1186/s12916-025-03897-3, doi:10.1186/s12916-025-03897-3. This article has 44 citations and is from a domain leading peer-reviewed journal.
(goldstein2024thefutureof pages 1-2): Amelia R Goldstein, Mallory Gersh, Gabriela Skovronsky, and Chailee Moss. The future of cervical cancer screening. International Journal of Women's Health, 16:1715-1731, Oct 2024. URL: https://doi.org/10.2147/ijwh.s474571, doi:10.2147/ijwh.s474571. This article has 43 citations and is from a peer-reviewed journal.
(malevolti2023doseriskrelationshipsbetween pages 5-6): Maria Chiara Malevolti, Alessandra Lugo, Marco Scala, Silvano Gallus, Giuseppe Gorini, Alessio Lachi, and Giulia Carreras. Dose-risk relationships between cigarette smoking and cervical cancer: a systematic review and meta-analysis. European Journal of Cancer Prevention, 32:171-183, Nov 2023. URL: https://doi.org/10.1097/cej.0000000000000773, doi:10.1097/cej.0000000000000773. This article has 50 citations and is from a peer-reviewed journal.
(malevolti2023doseriskrelationshipsbetween pages 1-2): Maria Chiara Malevolti, Alessandra Lugo, Marco Scala, Silvano Gallus, Giuseppe Gorini, Alessio Lachi, and Giulia Carreras. Dose-risk relationships between cigarette smoking and cervical cancer: a systematic review and meta-analysis. European Journal of Cancer Prevention, 32:171-183, Nov 2023. URL: https://doi.org/10.1097/cej.0000000000000773, doi:10.1097/cej.0000000000000773. This article has 50 citations and is from a peer-reviewed journal.
(malevolti2023doseriskrelationshipsbetween pages 6-7): Maria Chiara Malevolti, Alessandra Lugo, Marco Scala, Silvano Gallus, Giuseppe Gorini, Alessio Lachi, and Giulia Carreras. Dose-risk relationships between cigarette smoking and cervical cancer: a systematic review and meta-analysis. European Journal of Cancer Prevention, 32:171-183, Nov 2023. URL: https://doi.org/10.1097/cej.0000000000000773, doi:10.1097/cej.0000000000000773. This article has 50 citations and is from a peer-reviewed journal.
(jouya2026cervicalcancerepidemiology pages 12-13): Sara Jouya, Zahra Shahabinia, Afrooz Mazidimoradi, Leila Allahqoli, Hamid Salehiniya, and Do-Youn Lee. Cervical cancer epidemiology: global incidence, mortality, survival, risk factors, and equity in hpv screening and vaccination. Journal of Clinical Medicine, 15:1079, Jan 2026. URL: https://doi.org/10.3390/jcm15031079, doi:10.3390/jcm15031079. This article has 4 citations.
(shao2026globaltrendsand pages 1-2): Dongxuan Shao, Ping Wu, Huici Jiang, and Zhijie Wang. Global trends and future projections of cervical cancer burden: an integrated analysis of gbd 2021, un population and who hpv vaccination data. Frontiers in Public Health, Jan 2026. URL: https://doi.org/10.3389/fpubh.2026.1702186, doi:10.3389/fpubh.2026.1702186. This article has 3 citations.
(hohn20212020whoclassification pages 6-8): Anne Kathrin Höhn, Christine E. Brambs, Grit Gesine Ruth Hiller, Doris May, Elisa Schmoeckel, and Lars-Christian Horn. 2020 who classification of female genital tumors. Geburtshilfe und Frauenheilkunde, 81:1145-1153, Oct 2021. URL: https://doi.org/10.1055/a-1545-4279, doi:10.1055/a-1545-4279. This article has 495 citations and is from a peer-reviewed journal.
(zafar2025advancesandchallenges pages 7-8): Marhama Zafar, Narjes Sweis, Hitesh Kapoor, and Gerald Gantt. Advances and challenges in the treatment of hpv-associated lower genital tract cancers by immune checkpoint blockers: insights from basic and clinical science. Cancers, 17:1260, Apr 2025. URL: https://doi.org/10.3390/cancers17081260, doi:10.3390/cancers17081260. This article has 3 citations.
(zafar2025advancesandchallenges pages 20-21): Marhama Zafar, Narjes Sweis, Hitesh Kapoor, and Gerald Gantt. Advances and challenges in the treatment of hpv-associated lower genital tract cancers by immune checkpoint blockers: insights from basic and clinical science. Cancers, 17:1260, Apr 2025. URL: https://doi.org/10.3390/cancers17081260, doi:10.3390/cancers17081260. This article has 3 citations.
(zhou2024spatialtranscriptomicsreveals pages 1-2): Limin Zhou, Jiejie Liu, Peipei Yao, Xing Liu, Fei Chen, Yu Chen, Li Zhou, Chao Shen, You Zhou, Xin Du, and Junbo Hu. Spatial transcriptomics reveals unique metabolic profile and key oncogenic regulators of cervical squamous cell carcinoma. Journal of Translational Medicine, Dec 2024. URL: https://doi.org/10.1186/s12967-024-06011-y, doi:10.1186/s12967-024-06011-y. This article has 8 citations and is from a peer-reviewed journal.
(zhou2024spatialtranscriptomicsreveals pages 9-12): Limin Zhou, Jiejie Liu, Peipei Yao, Xing Liu, Fei Chen, Yu Chen, Li Zhou, Chao Shen, You Zhou, Xin Du, and Junbo Hu. Spatial transcriptomics reveals unique metabolic profile and key oncogenic regulators of cervical squamous cell carcinoma. Journal of Translational Medicine, Dec 2024. URL: https://doi.org/10.1186/s12967-024-06011-y, doi:10.1186/s12967-024-06011-y. This article has 8 citations and is from a peer-reviewed journal.
(zhou2024spatialtranscriptomicsreveals pages 14-17): Limin Zhou, Jiejie Liu, Peipei Yao, Xing Liu, Fei Chen, Yu Chen, Li Zhou, Chao Shen, You Zhou, Xin Du, and Junbo Hu. Spatial transcriptomics reveals unique metabolic profile and key oncogenic regulators of cervical squamous cell carcinoma. Journal of Translational Medicine, Dec 2024. URL: https://doi.org/10.1186/s12967-024-06011-y, doi:10.1186/s12967-024-06011-y. This article has 8 citations and is from a peer-reviewed journal.
(zhou2024spatialtranscriptomicsreveals pages 6-9): Limin Zhou, Jiejie Liu, Peipei Yao, Xing Liu, Fei Chen, Yu Chen, Li Zhou, Chao Shen, You Zhou, Xin Du, and Junbo Hu. Spatial transcriptomics reveals unique metabolic profile and key oncogenic regulators of cervical squamous cell carcinoma. Journal of Translational Medicine, Dec 2024. URL: https://doi.org/10.1186/s12967-024-06011-y, doi:10.1186/s12967-024-06011-y. This article has 8 citations and is from a peer-reviewed journal.
(zhou2024spatialtranscriptomicsreveals media 5eccae45): Limin Zhou, Jiejie Liu, Peipei Yao, Xing Liu, Fei Chen, Yu Chen, Li Zhou, Chao Shen, You Zhou, Xin Du, and Junbo Hu. Spatial transcriptomics reveals unique metabolic profile and key oncogenic regulators of cervical squamous cell carcinoma. Journal of Translational Medicine, Dec 2024. URL: https://doi.org/10.1186/s12967-024-06011-y, doi:10.1186/s12967-024-06011-y. This article has 8 citations and is from a peer-reviewed journal.
(zhou2024spatialtranscriptomicsreveals media 8e0f5cba): Limin Zhou, Jiejie Liu, Peipei Yao, Xing Liu, Fei Chen, Yu Chen, Li Zhou, Chao Shen, You Zhou, Xin Du, and Junbo Hu. Spatial transcriptomics reveals unique metabolic profile and key oncogenic regulators of cervical squamous cell carcinoma. Journal of Translational Medicine, Dec 2024. URL: https://doi.org/10.1186/s12967-024-06011-y, doi:10.1186/s12967-024-06011-y. This article has 8 citations and is from a peer-reviewed journal.
(zhou2024spatialtranscriptomicsreveals media c108e719): Limin Zhou, Jiejie Liu, Peipei Yao, Xing Liu, Fei Chen, Yu Chen, Li Zhou, Chao Shen, You Zhou, Xin Du, and Junbo Hu. Spatial transcriptomics reveals unique metabolic profile and key oncogenic regulators of cervical squamous cell carcinoma. Journal of Translational Medicine, Dec 2024. URL: https://doi.org/10.1186/s12967-024-06011-y, doi:10.1186/s12967-024-06011-y. This article has 8 citations and is from a peer-reviewed journal.
(zhou2024spatialtranscriptomicsreveals media f3ff4cda): Limin Zhou, Jiejie Liu, Peipei Yao, Xing Liu, Fei Chen, Yu Chen, Li Zhou, Chao Shen, You Zhou, Xin Du, and Junbo Hu. Spatial transcriptomics reveals unique metabolic profile and key oncogenic regulators of cervical squamous cell carcinoma. Journal of Translational Medicine, Dec 2024. URL: https://doi.org/10.1186/s12967-024-06011-y, doi:10.1186/s12967-024-06011-y. This article has 8 citations and is from a peer-reviewed journal.
(fischerova2024theroleof pages 7-8): Daniela Fischerova, Filip Frühauf, Andrea Burgetova, Ingfrid S. Haldorsen, Elena Gatti, and David Cibula. The role of imaging in cervical cancer staging: esgo/estro/esp guidelines (update 2023). Cancers, 16:775, Feb 2024. URL: https://doi.org/10.3390/cancers16040775, doi:10.3390/cancers16040775. This article has 50 citations.
(dey2025immunotherapyincervical pages 7-8): Treshita Dey and Sushma Agrawal. Immunotherapy in cervical cancer: an innovative approach for better treatment outcomes. Exploration of Targeted Anti-tumor Therapy, Mar 2025. URL: https://doi.org/10.37349/etat.2025.1002296, doi:10.37349/etat.2025.1002296. This article has 21 citations.

Ask OpenScientist

OpenScientist Report

Subtypes

Pathophysiology

Pathograph

Phenotypes

Treatments

Environmental Factors

Source YAML

References & Deep Research

Deep Research

1. Disease Information

1.1 Definition and current understanding

1.2 Key identifiers and classification

1.3 Synonyms/alternative names

1.4 Evidence provenance (aggregated vs patient-level)

2. Etiology

2.1 Primary causal factors

2.2 Risk factors (human epidemiology)

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes (clinical presentation)

3.1 Common phenotypes (signs/symptoms)

3.2 Suggested HPO terms (not exhaustive)

3.3 Quality-of-life impact

4. Genetic / Molecular Information

4.1 Somatic driver landscape (high-level)

4.2 HPV-associated vs HPV-independent molecular patterns

4.3 Epigenetics

4.4 Pathogenic variants (germline)

5. Environmental Information

5.1 Lifestyle/environmental contributors

5.2 Infectious agents

6. Mechanism / Pathophysiology

6.1 Causal chain (HPV to CSCC)

6.2 Immune microenvironment and checkpoint biology

6.3 Spatial transcriptomics: metabolic states and oncogenic regulators (2024 primary study)

6.4 Suggested ontology mappings

7. Anatomical Structures Affected

7.1 Organ and tissue level

7.2 Subcellular/localization (GO-CC suggestions)

8. Temporal Development (natural history)

9. Inheritance and Population

9.1 Epidemiology (recent global statistics)

9.2 Inheritance pattern

10. Diagnostics

10.1 Screening and diagnostic pathway (current practice and developments)

10.2 Pathology / biomarkers

10.3 Imaging/staging (2023 guideline update summarized in 2024)

11. Outcome / Prognosis

11.1 Prognostic biomarkers and microenvironment

11.2 Advanced disease outcomes and unmet need

12. Treatment

12.1 Standard local therapy (curative intent)

12.2 Systemic therapy—immune checkpoint inhibitors (advanced/recurrent/metastatic)

12.3 Treatment-related toxicity (high level)

12.4 Suggested MAXO mappings (examples)

13. Prevention

13.1 WHO elimination strategy and targets

13.2 Screening technology modernization (2024)

14. Other Species / Natural Disease

15. Model Organisms

Recent developments (2023–2024 highlights)

Embedded figure evidence (spatial transcriptomics)

Key gaps (not found in retrieved sources in this session)